Low-Dose Maintenance Therapy With Infliximab Prevents Postsurgical Recurrence of Crohn's Disease

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 7, 2010, Pages

  Sorrentino, Dario ^a   Paviotti, Alberto ^a   Terrosu, Giovanni ^a   Avellini, Claudio ^a   Geraci, Marco ^b   Zarifi, Dimitra ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Crohn's Disease; Infliximab; Postoperative Recurrence; Prevention

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CALGRANULIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISONE; BIOLOGICAL MARKER; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENDOSCOPY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INTESTINE MUCOSA; MALE; PROSPECTIVE STUDY; RECURRENT DISEASE; BLOOD; CHEMISTRY; COHORT ANALYSIS; FECES; FOLLOW UP; MIDDLE AGED; SECONDARY PREVENTION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; BIOMARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COHORT STUDIES; CROHN DISEASE; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INFLIXIMAB; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84876457416     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.01.016     Document Type: Article

References (37)

1. Sandborn W.J., and Feagan B.G. The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. Gastroenterology 127 (2004) 990-993
2. Sorrentino D., Terrosu G., Avellini C., et al. Prevention of postoperative recurrence of Crohn's disease by infliximab. Eur J Gastroenterol Hepatol 18 (2006) 457-459
3. Sorrentino D., Terrosu G., Avellini A., et al. Infliximab and low dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn's disease. Arch Intern Med 167 (2007) 1804-1810
4. Regueiro M., Schraut W., Baidoo L., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 136 (2009) 441-450
5. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
6. Hanauer S.B. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?. Gut 56 (2007) 1181-1183
7. Hanauer S.B., Korelitz B.I., Rutgeerts P., et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127 (2004) 723-729
8. Rutgeerts P., Geboes K., Vantrappen G., et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 99 (1990) 956-963
9. Sandborn W.J., Feagan B.G., Hanauer S.B., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122 (2002) 512-530
10. Rutgeerts P., Geboes K., Vantrappen G., et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 25 (1984) 665-672
11. D'Haens G.R., Geboes K., Peeters M., et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114 (1998) 262-267
12. Summerton C.B., Longlands M.G., Wiener K., et al. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 14 (2002) 841-845
13. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 6 (1979) 65-70
14. Koenker R., and Bassett G. Regression quantiles. Econometrica 46 (1978) 33-50
15. Bassett G., and Koenker R. Tests of linear hypotheses and L1 estimation. Econometrica 50 (1982) 1577-1583
16. Bernell O., Lapidus A., and Hellers G. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease. Br J Surg 87 (2000) 1697-1701
17. Peyrin-Biroulet L., Deltenre P., Ardizzone S., et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 104 (2009) 2089-2096
18. Sorrentino D., and Paviotti A. Postsurgical recurrence of Crohn's disease: the beginning of the end?. Gastroenterology 137 (2009) 1181-1182
19. McLeod R.S., Wolff B.G., Steinhart A.H., et al. Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease. Gastroenterology 113 (1997) 1823-1827
20. Sachar D.B. Recurrence rates in Crohn's disease: predicting the future and predicting the past. Gut 55 (2006) 1069-1070
21. Bratcher J.M., and Korelitz B.I. Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin Drug Saf 5 (2006) 9-16
22. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 295 (2006) 2275-2278
23. Gisbert J.P., and Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 104 (2009) 760-767
24. Jois R.N., Leeder J., Gibb A., et al. Low-dose infliximab treatment for ankylosing spondylitis-clinically- and cost-effective. Rheumatology 45 (2006) 1566-1569
25. Sidiropoulos P., Kritikos H.D., Siakka P., et al. Low dose of infliximab is inadequate in most patients with spondylarthropathies. Clin Exp Rheumatol 23 (2005) 513-516
26. van den Bemt B.J.F., den Broeder A.A., Snijders G.F., et al. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Ann Rheum Dis 67 (2008) 1697-1701
27. Peyrin-Biroulet L., Bigard M.A., Malesci A., et al. Step-up and top-down approaches to the treatment of Crohn's disease: early may already be too late. Gastroenterology 135 (2008) 1420-1422
28. Schnitzler F., Fidder H., Ferrante M., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 58 (2009) 492-500
29. Schoepfer A.M., Trummler M., Seeholzer P., et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 14 (2008) 32-39
30. Lewis J.D. C-reactive protein: anti-placebo or predictor of response. Gastroenterology 129 (2005) 1114-1116
31. Vermeire S., Van Assche G., and Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut 55 (2006) 426-431
32. Camma C., Giunta M., Rosselli M., et al. Mesalamine in the maintenance treatment of Crohn's disease: a metaanalysis adjusted for confounding variables. Gastroenterology 113 (1997) 1465-1473
33. Renna S., Cammà C., Modesto I., et al. Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology 135 (2008) 1500-1509
34. Olaison G., Smedh K., and Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 33 (1992) 331-335
35. Onali S., Petruzziello C., Calabrese E., et al. Frequency, pattern, and risk factors of postoperative recurrence of Crohn's disease after resection different from ileo-colonic. J Gastrointest Surg 13 (2009) 246-252
36. Cohen R.D., and Thomas T. Economics of the use of biologics in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am 35 (2006) 867-882
37. Lewis J.D., Schoenfeld P., and Lichtenstein G.R. An evidence-based approach to studies of the natural history of gastrointestinal diseases: recurrence of symptomatic Crohn's disease after surgery. Clin Gastroenterol Hepatol 1 (2003) 229-236